Vita Therapeutics, Inc. announced that it has entered into series A preferred stock purchase agreement and will issue 10,000,000 series A preferred stock at a price of $1 per share for gross proceeds of $10,000,000, 7,684,599 series A-1 preferred stock at a price of approximately $1.3013 per share for gross proceeds of $10,000,000, and 3,053,796 series A-2 preferred stock at a price of $0.8 per share for gross proceeds of $2,443,036.8, for aggregate gross proceeds of $22,443,036.8 on January 12, 2021. The company will also issue option, warrant or other right to acquire another security in the transaction. The shares are convertible and non-redeemable. The series A shares, series A-1 shares and series A-2 shares will be convertible into common shares at a fixed conversion price of $1, $1.3013, and $0.8 per share respectively. The company will receive $20,000,000 pursuant to exemption provided under Regulation D.